Infosecurity outlines key recommendations for CISOs and security teams to implement safeguards for AI-assisted coding ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...
Researchers discovered an appetite-suppressing molecule in python blood. If one day turned into a medication, it might lack ...
Hosted on MSN
Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound?
A month has gone by since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have lost about 16.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results